Transgenic Group (2342) · RiskFirst stated

Revenue decline due to delays in launching new services in advanced medical care and pathological diagnosis

First written in FY2017. . Latest entry: FY2017.

1entries

1years

0from disclosures

Share on X

How it moved

Same theme, other companies

New Product Development and Launch Delay RiskA theme 24 companies write about · 24 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2021: 3 of 8 companies on the "Worse" side.

2 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 24 companies compared. The sentences above are computed from all 24.

Full recordFilings, disclosures and news, newest first

FY2017First statedAnnual report
「In the advanced medical and pathological diagnostics businesses of the subsidiary 株式会社ジェネティックラボ, revenue declined due to delays in launching new services, leaving consolidated net sales for the fiscal year under review up only slightly, by 0.6% year on year.」
The company states that delays in launching new services actually occurred and were a factor behind the revenue decline in the advanced medical and pathological diagnostics businesses.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Transgenic Group yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.